The Impact of Charlson Comorbidity Index on De Novo Cardiac Implantable Electronic Device Procedural Outcomes in the United States

Mohamed, Mohamed O.; Van Spall, Harriette G.C.; Morillo, Carlos; Wilton, Steve B.; Kontopantelis, Evangelos; Rashid, Muhammad; Wu, Pensee; Patwala, Ashish; Mamas, Mamas

Abstract

OBJECTIVE: To investigate the utility of Charlson comorbidity index (CCI) as a measure of comorbidity burden to predict procedural outcomes after de novo cardiac implantable electronic device (CIED) implantation. METHODS: All de novo CIED implantations in the United States National Inpatient Sample between 2015 and 2018 were retrospectively analyzed, stratified by CCI score (0=no comorbidity burden, 1=mild, 2=moderate, =3=severe). Multivariable logistic regression models were performed to examine the association between unit CCI score (scale) and in-hospital outcomes (major adverse cerebrovascular and cardiovascular events [MACCE]: composite of all-cause mortality, acute ischemic stroke, thoracic and cardiac complications, and device-related complications; and MACCE individual components). RESULTS: Of 474,475 CIED procedures, the distribution of CCI score was as follows: CCI=0 (17.7%), CCI=1 (21.8%), CCI=2 (18.7%), and CCI=3+ (41.8%). Charlson comorbidity index score was associated with increased odds ratios of MACCE (1.10; 95% CI, 1.09 to 1.11), all-cause mortality (1.23; 95% CI, 1.21 to 1.25), and acute stroke (1.45; 95% CI, 1.44 to 1.46). This finding was consistent across all CIED groups except the cardiac resynchronization therapy groups in which CCI was not associated with increased risk of mortality. A higher CCI score was not associated with increased odds of procedural (thoracic and cardiac) and device-related complications. CONCLUSION: In a nationwide cohort of CIED procedures, higher comorbidity burden as measured by CCI score was associated with an increased risk of in-hospital mortality and acute ischemic stroke, but not procedure-related (thoracic and cardiac) or device-related complications. Objective assessment of comorbidity burden is important to risk-stratify patients undergoing CIED implantation for better prognostication of their in-hospital survival.

Citation

Mohamed, M. O., Van Spall, H. G., Morillo, C., Wilton, S. B., Kontopantelis, E., Rashid, M., …Mamas, M. (2022). The Impact of Charlson Comorbidity Index on De Novo Cardiac Implantable Electronic Device Procedural Outcomes in the United States. Mayo Clinic Proceedings, 97(1), 88 - 100. https://doi.org/10.1016/j.mayocp.2021.06.029

• Journal Article Type: Article
• Acceptance Date: Dec 1, 2021
• Online Publication Date: Dec 1, 2021
• Publication Date: 2022-01
• Journal: Mayo Clinic Proceedings
• Print ISSN: 0025-6196
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 97
• Issue: 1
• Pages: 88 - 100
• DOI: https://doi.org/10.1016/j.mayocp.2021.06.029
• Publisher URL: https://www.sciencedirect.com/science/article/abs/pii/S002561962100611X